(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

Scientific breakthroughs are fueling new hope in women’s health. But experts warn that persistent gaps in funding and access could stall that progress.

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

A study on long-acting ART shows 92% viral suppression among HIV-1 viremia patients in the U.S. South, offering hope for high ...

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Amidst limited doses, priority will be given to those at substantial risk of HIV acquisition, such as adolescent girls and young women who are engaged in marital or concurrent sexual partnerships." ...

The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...